Galectin Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +668.1% | +29.2% | +250.5% | +38.8% | -55.3% | +28.2% | -72.0% | -60.5% | -38.1% | +1,345.0% | +5.0% | +44.6% | +12.0% | +177.0% | -11.0% | -40.2% | -73.7% | +116.4% | +438.2% | -38.9% | +41.3% | -49.1% | +32.5% | -38.0% | +11.6% | |
| – | +648.5% | +26.8% | +286.0% | +40.6% | -56.6% | +26.5% | -76.6% | -72.6% | -20.0% | +1,937.8% | +4.9% | +46.4% | +12.3% | +177.5% | -11.0% | -40.2% | -75.8% | +131.3% | +445.8% | -38.9% | +41.9% | -50.9% | +34.8% | -37.7% | +12.7% | |
| – | +610.1% | +28.8% | +296.0% | +40.7% | -58.3% | -82.7% | +70.6% | -75.9% | -21.1% | +2,247.0% | +8.6% | +46.4% | +12.0% | +177.7% | -11.3% | -40.6% | -80.1% | +170.3% | +475.3% | -42.8% | +46.1% | -53.1% | +38.0% | -41.1% | +17.2% | |
| – | +610.1% | +28.8% | +296.0% | +40.7% | -58.3% | +29.3% | -77.2% | -75.9% | -21.1% | +2,247.0% | +8.6% | +46.4% | +12.0% | +177.7% | -11.3% | -40.6% | -80.1% | +170.3% | +475.3% | -42.8% | +46.1% | -53.1% | +38.0% | -41.1% | +17.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +58.0% | -18.6% | -28.5% | -41.7% | +86.7% | -34.8% | -45.2% | -57.5% | -58.8% | -14.3% | +33.3% | -62.5% | -66.7% | -100.0% | – | – | – | – | -42.9% | -85.4% | – | – | – | – | |
| – | +461.2% | +51.6% | -99.8% | +99,900.0% | +34.0% | +22.5% | -2.3% | -10.0% | -75.1% | -30.4% | -7.7% | -16.7% | -23.3% | -34.8% | -46.7% | -87.5% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +461.2% | +51.6% | +58.7% | +15.6% | +34.0% | +22.5% | -2.3% | -10.0% | -75.1% | -30.4% | -7.7% | -16.7% | -23.3% | -34.8% | -46.7% | -87.5% | -100.0% | – | – | – | – | – | – | – | – | |
| – | +205.9% | +21.1% | -43.3% | +165.9% | +37.3% | +362.7% | -26.3% | -75.1% | +318.0% | +63.0% | -72.3% | -25.8% | +51.2% | -31.5% | -20.1% | +177.9% | -21.5% | -29.0% | +36.2% | +88.3% | +625.2% | +36.4% | +65.4% | +36.3% | +20.9% | |
| – | +205.9% | +21.1% | -43.3% | +165.9% | +37.3% | +334.0% | -56.6% | -58.5% | -2.5% | +68.3% | +25.1% | -26.0% | +51.8% | -31.5% | -20.1% | +177.9% | -21.5% | -29.0% | +33.8% | +91.5% | +67.3% | +44.0% | +20.5% | +125.9% | -77.3% | |
| – | +143.8% | -92.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +12.8% | -81.8% | +400.0% | +15.0% | +45,847.8% | -99.9% | |
| – | +195.3% | +28.2% | -45.2% | +24.1% | +43.2% | +15.3% | +76.8% | -25.6% | -50.6% | -43.4% | +207.2% | +3.4% | +91.9% | +18.9% | -50.6% | +103.1% | -33.2% | -51.2% | +459.3% | -22.2% | +39.7% | +115.5% | +65.3% | -12.1% | -42.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +37.1% | +80.1% | +18.6% | +57.1% | |
| – | +2,331.7% | +32.9% | +371.7% | +32.5% | -64.5% | -100.6% | – | – | – | – | – | +80.1% | +3.9% | +240.0% | -10.5% | -52.0% | -90.1% | +478.2% | +561.0% | -46.9% | -89.2% | -1,330.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +10.0% | +20.4% | +30.5% | +20.6% | +6.1% | +4.2% | +36.9% | +20.1% | +3.1% | +16.6% | +27.7% | +26.2% | +11.5% | +29.5% | +10.4% | +21.1% | +21.6% | +11.0% | +32.5% | +9.2% | +2.6% | +1.5% | +1.3% | +3.6% | +2.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.